Strategic Sponsorship Will Provide Innovative Technology and Nurture Promising Biotechnology Startup
SANTA CLARA, Calif., September 19, 2017
Agilent Technologies Inc. (NYSE: A) has announced a platinum sponsorship agreement with LabCentral,
a biotech innovation hub based in Cambridge, Massachusetts. LabCentral is an independent, shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups.
As a platinum sponsor, Agilent will equip LabCentral’s shared laboratory workspace with a variety of Agilent technology. Instruments will include a high-resolution mass spectrometry system, as well as a cell analysis extracellular flux (XF) analyzer. Also, Agilent will fund a high-potential biotech startup company at LabCentral via a contest to award a Golden Ticket. The Agilent-sponsored Golden Ticket is good for one individual bench in LabCentral’s shared facility for one year. Online applications for the Golden Ticket open on October 2, 2017, and will be accepted until November 1, 2017, at 12:00 Noon PST. The finalists will present to an esteemed review panel at a public event at LabCentral on November 16, 2017. Learn more at www.agilent.com/en/promotions/goldenticket.
“Agilent is committed to supporting the next generation of scientific pioneers, and what better place to do so than in one of our nation’s fastest growing biotech communities,” said Darlene Solomon, senior vice president and chief technology officer for Agilent. “We couldn’t be more proud to offer our technologies to LabCentral residents, and our support to emerging biotech to help accelerate innovation in critical areas that can improve human health.”
“We’re honored to welcome Agilent as a platinum sponsor, which will enable us to build out significant extra analytical capacity for our startups to use,” said Johannes Fruehauf, M.D., Ph.D., cofounder, and president for LabCentral. “In addition, we are especially happy that Agilent has agreed to become a Golden Ticket sponsor. The team has come up with an exciting process for identifying the winner—and I look forward to participating.”
LabCentral offers a supportive and nurturing environment designed to inspire interaction and collaboration. Startups work side by side on some of the most exciting potential breakthroughs in diagnostics and therapeutics, and prevention—across the spectrum of diseases.
Biopharma is a fast-growing market for Agilent, and Cambridge is a hub of innovation in this field.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets.With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.
About LabCentral (www.labcentral.org; twitter @labcentral)
LabCentral is a first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub. Designed as a launchpad for high-potential life-sciences and biotech startups, it offers everything startups need to begin laboratory operations on day one and move their science forward faster and more cost-efficiently. This includes: fully permitted laboratory and office space, first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support. A private, nonprofit institution, LabCentral’s first site opened in 2013, thanks to a capital grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation.
# # #
Contact:
Naomi Goumillout
Agilent Technologies, Inc.
+1 781 266 2819
naomi.goumillout@agilent.com
Caroline A. Grossman
LabCentral
+1 781 771 5579
cgrossman@labcentral.org
| http://www.agilent.com/about/newsroom/presrel/2017/19sep-ca17029.html |